Aegerion Pharmaceuticals (AEGR +8.5%) says the FDA has provided a clear and executable pathway...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR +8.5%) says the FDA has provided a clear and executable pathway for the company to file a New Drug Application for its lead investigational therapeutic, lomitapide, based upon Phase III clinical trial results in 29 patients with HoFH, with a primary endpoint of LDL-C reduction.